-+ 0.00%
-+ 0.00%
-+ 0.00%
According to the Galaxy Securities Research Report, the outbreak of TCE innovative drug-related transactions is expected to become a new cradle for the birth of major new drugs. Following dual antibodies and ADC, TCE is becoming a new trading hotspot in the field of innovative drugs. As the racetrack continues to heat up, BD competition for high-quality TCE assets has accelerated markedly. In 2025 alone, 10 Chinese pharmaceutical companies will launch TCE projects overseas, with a cumulative potential transaction amount of more than 7 billion US dollars. TCE has completed technical and commercial double verification of hematoma. The targets are CD19/CD20, BCMA/GPRC5D, and the indications are gradually advancing to the front line. Furthermore, TCE can deeply remove autoreactive B-cells/plasma cells by targeting CD19/CD20/BCMA and achieve immune rearrangement, which is expected to fundamentally change the treatment paradigm for autoimmune diseases such as SLE and RA, but it is still in the exploration stage, and no products have been approved. China has become an important source of global TCE innovation. As of mid-2026, Chinese pharmaceutical companies have promoted more than 10 TCE projects, covering three-antibody TCE, shielded TCE, 2+1 structures, etc.
Share
Listen to the news
According to the Galaxy Securities Research Report, the outbreak of TCE innovative drug-related transactions is expected to become a new cradle for the birth of major new drugs. Following dual antibodies and ADC, TCE is becoming a new trading hotspot in the field of innovative drugs. As the racetrack continues to heat up, BD competition for high-quality TCE assets has accelerated markedly. In 2025 alone, 10 Chinese pharmaceutical companies will push TCE projects overseas, with a cumulative potential transaction amount of more than 7 billion US dollars. TCE has completed technical and commercial double verification of hematoma. The targets are CD19/CD20, BCMA/GPRC5D, and the indications are gradually advancing to the front line. Furthermore, TCE can deeply remove autoreactive B-cells/plasma cells by targeting CD19/CD20/BCMA and achieve immune rearrangement, which is expected to fundamentally change the treatment paradigm for autoimmune diseases such as SLE and RA, but it is still in the exploration stage, and no products have been approved. China has become an important source of global TCE innovation. As of mid-2026, Chinese pharmaceutical companies have promoted more than 10 TCE projects, covering three-antibody TCE, shielded TCE, 2+1 structures, etc.
Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.
What's Trending